Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy

Thomas Jandl, Ekaterina Revskaya, Zewei Jiang, Matthew Harris, Olena Dorokhova, Dina Tsukrov, Arturo Casadevall, Ekaterina Dadachova

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: In spite of recently approved B-RAF inhibitors and immunomodulating antibodies, metastatic melanoma has poor prognosis and novel treatments are needed. Melanoma stem cells (MSC) have been implicated in the resistance of this tumor to chemotherapy. Recently we demonstrated in a Phase I clinical trial in patients with metastatic melanoma that radioimmunotherapy (RIT) with 188-Rhenium(188Re)-6D2 antibody to melanin was a safe and effective modality. Here we investigated the interaction of MSC with RIT as a possible mechanism for RIT efficacy. Methods: Mice bearing A2058 melanoma xenografts were treated with either 1.5mCi 188Re-6D2 antibody, saline, unlabeled 6D2 antibody or 188Re-labeled non-specific IgM. Results: On Day 28 post-treatment the tumor size in the RIT group was 4-times less than in controls (P. <. 0.001). The tumors were analyzed by immunohistochemistry and FACS for two MSC markers - chemoresistance mediator ABCB5 and H3K4 demethylase JARID1B. There were no significant differences between RIT and control groups in percentage of ABCB5 or JARID1B-positive cells in the tumor population. Our results demonstrate that unlike chemotherapy, which kills tumor cells but leaves behind MSC leading to recurrence, RIT kills MSC at the same rate as the rest of tumor cells. Conclusions: These results have two main implications for melanoma treatment and possibly other cancers. First, the susceptibility of ABCB5. + and JARID1B. +. cells to RIT in melanoma might be indicative of their susceptibility to antibody-targeted radiation in other cancers where they are present as well. Second, specifically targeting cancer stem cells with radiolabeled antibodies to ABCB5 or JARID1B might help to completely eradicate cancer stem cells in various cancers.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalNuclear Medicine and Biology
Volume40
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Radioimmunotherapy
Experimental Melanomas
Melanoma
Stem Cells
Rhenium
Neoplasms
Antibodies
Neoplastic Stem Cells
Drug Therapy
Clinical Trials, Phase I
Melanins
Heterografts
Immunoglobulin M
Therapeutics
Immunohistochemistry
Radiation

Keywords

  • Cancer stem cells
  • Clinical trial
  • Melanin
  • Melanoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Jandl, T., Revskaya, E., Jiang, Z., Harris, M., Dorokhova, O., Tsukrov, D., ... Dadachova, E. (2013). Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. Nuclear Medicine and Biology, 40(2), 177-181. https://doi.org/10.1016/j.nucmedbio.2012.10.006

Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. / Jandl, Thomas; Revskaya, Ekaterina; Jiang, Zewei; Harris, Matthew; Dorokhova, Olena; Tsukrov, Dina; Casadevall, Arturo; Dadachova, Ekaterina.

In: Nuclear Medicine and Biology, Vol. 40, No. 2, 02.2013, p. 177-181.

Research output: Contribution to journalArticle

Jandl, T, Revskaya, E, Jiang, Z, Harris, M, Dorokhova, O, Tsukrov, D, Casadevall, A & Dadachova, E 2013, 'Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy', Nuclear Medicine and Biology, vol. 40, no. 2, pp. 177-181. https://doi.org/10.1016/j.nucmedbio.2012.10.006
Jandl, Thomas ; Revskaya, Ekaterina ; Jiang, Zewei ; Harris, Matthew ; Dorokhova, Olena ; Tsukrov, Dina ; Casadevall, Arturo ; Dadachova, Ekaterina. / Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. In: Nuclear Medicine and Biology. 2013 ; Vol. 40, No. 2. pp. 177-181.
@article{bd2969f76b724323869b7f97c6104ea5,
title = "Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy",
abstract = "Introduction: In spite of recently approved B-RAF inhibitors and immunomodulating antibodies, metastatic melanoma has poor prognosis and novel treatments are needed. Melanoma stem cells (MSC) have been implicated in the resistance of this tumor to chemotherapy. Recently we demonstrated in a Phase I clinical trial in patients with metastatic melanoma that radioimmunotherapy (RIT) with 188-Rhenium(188Re)-6D2 antibody to melanin was a safe and effective modality. Here we investigated the interaction of MSC with RIT as a possible mechanism for RIT efficacy. Methods: Mice bearing A2058 melanoma xenografts were treated with either 1.5mCi 188Re-6D2 antibody, saline, unlabeled 6D2 antibody or 188Re-labeled non-specific IgM. Results: On Day 28 post-treatment the tumor size in the RIT group was 4-times less than in controls (P. <. 0.001). The tumors were analyzed by immunohistochemistry and FACS for two MSC markers - chemoresistance mediator ABCB5 and H3K4 demethylase JARID1B. There were no significant differences between RIT and control groups in percentage of ABCB5 or JARID1B-positive cells in the tumor population. Our results demonstrate that unlike chemotherapy, which kills tumor cells but leaves behind MSC leading to recurrence, RIT kills MSC at the same rate as the rest of tumor cells. Conclusions: These results have two main implications for melanoma treatment and possibly other cancers. First, the susceptibility of ABCB5. + and JARID1B. +. cells to RIT in melanoma might be indicative of their susceptibility to antibody-targeted radiation in other cancers where they are present as well. Second, specifically targeting cancer stem cells with radiolabeled antibodies to ABCB5 or JARID1B might help to completely eradicate cancer stem cells in various cancers.",
keywords = "Cancer stem cells, Clinical trial, Melanin, Melanoma, Radioimmunotherapy",
author = "Thomas Jandl and Ekaterina Revskaya and Zewei Jiang and Matthew Harris and Olena Dorokhova and Dina Tsukrov and Arturo Casadevall and Ekaterina Dadachova",
year = "2013",
month = "2",
doi = "10.1016/j.nucmedbio.2012.10.006",
language = "English (US)",
volume = "40",
pages = "177--181",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy

AU - Jandl, Thomas

AU - Revskaya, Ekaterina

AU - Jiang, Zewei

AU - Harris, Matthew

AU - Dorokhova, Olena

AU - Tsukrov, Dina

AU - Casadevall, Arturo

AU - Dadachova, Ekaterina

PY - 2013/2

Y1 - 2013/2

N2 - Introduction: In spite of recently approved B-RAF inhibitors and immunomodulating antibodies, metastatic melanoma has poor prognosis and novel treatments are needed. Melanoma stem cells (MSC) have been implicated in the resistance of this tumor to chemotherapy. Recently we demonstrated in a Phase I clinical trial in patients with metastatic melanoma that radioimmunotherapy (RIT) with 188-Rhenium(188Re)-6D2 antibody to melanin was a safe and effective modality. Here we investigated the interaction of MSC with RIT as a possible mechanism for RIT efficacy. Methods: Mice bearing A2058 melanoma xenografts were treated with either 1.5mCi 188Re-6D2 antibody, saline, unlabeled 6D2 antibody or 188Re-labeled non-specific IgM. Results: On Day 28 post-treatment the tumor size in the RIT group was 4-times less than in controls (P. <. 0.001). The tumors were analyzed by immunohistochemistry and FACS for two MSC markers - chemoresistance mediator ABCB5 and H3K4 demethylase JARID1B. There were no significant differences between RIT and control groups in percentage of ABCB5 or JARID1B-positive cells in the tumor population. Our results demonstrate that unlike chemotherapy, which kills tumor cells but leaves behind MSC leading to recurrence, RIT kills MSC at the same rate as the rest of tumor cells. Conclusions: These results have two main implications for melanoma treatment and possibly other cancers. First, the susceptibility of ABCB5. + and JARID1B. +. cells to RIT in melanoma might be indicative of their susceptibility to antibody-targeted radiation in other cancers where they are present as well. Second, specifically targeting cancer stem cells with radiolabeled antibodies to ABCB5 or JARID1B might help to completely eradicate cancer stem cells in various cancers.

AB - Introduction: In spite of recently approved B-RAF inhibitors and immunomodulating antibodies, metastatic melanoma has poor prognosis and novel treatments are needed. Melanoma stem cells (MSC) have been implicated in the resistance of this tumor to chemotherapy. Recently we demonstrated in a Phase I clinical trial in patients with metastatic melanoma that radioimmunotherapy (RIT) with 188-Rhenium(188Re)-6D2 antibody to melanin was a safe and effective modality. Here we investigated the interaction of MSC with RIT as a possible mechanism for RIT efficacy. Methods: Mice bearing A2058 melanoma xenografts were treated with either 1.5mCi 188Re-6D2 antibody, saline, unlabeled 6D2 antibody or 188Re-labeled non-specific IgM. Results: On Day 28 post-treatment the tumor size in the RIT group was 4-times less than in controls (P. <. 0.001). The tumors were analyzed by immunohistochemistry and FACS for two MSC markers - chemoresistance mediator ABCB5 and H3K4 demethylase JARID1B. There were no significant differences between RIT and control groups in percentage of ABCB5 or JARID1B-positive cells in the tumor population. Our results demonstrate that unlike chemotherapy, which kills tumor cells but leaves behind MSC leading to recurrence, RIT kills MSC at the same rate as the rest of tumor cells. Conclusions: These results have two main implications for melanoma treatment and possibly other cancers. First, the susceptibility of ABCB5. + and JARID1B. +. cells to RIT in melanoma might be indicative of their susceptibility to antibody-targeted radiation in other cancers where they are present as well. Second, specifically targeting cancer stem cells with radiolabeled antibodies to ABCB5 or JARID1B might help to completely eradicate cancer stem cells in various cancers.

KW - Cancer stem cells

KW - Clinical trial

KW - Melanin

KW - Melanoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84872907320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872907320&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2012.10.006

DO - 10.1016/j.nucmedbio.2012.10.006

M3 - Article

C2 - 23146306

AN - SCOPUS:84872907320

VL - 40

SP - 177

EP - 181

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 2

ER -